Ferring Bravelle approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ferring's highly purified, human-derived follicle-stimulating hormone (FSH) urofollitropin will be priced 25% to 35% lower than other FSH therapies on the market, including recombinant products such as Serono's Gonal-F and Organon's Follistim, the firm says. Bravelle, available in subcutaneous and intramuscular injections, cleared FDA May 6 for induction of ovulation. An application for use in in vitro fertilization was submitted earlier this yea
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.